The FDA has approved a self-injectable formulation of Xolair for appropriate patients with moderate to severe persistent allergic asthma, nasal...
xolair fda
Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to...
A one-month supply of omalizumab will cost patients between $541 and $2,706, depending on the dosage. This price is much...
Xolair was first approved in 2003 to treat adults and children 12 years of age and older with moderate to...
